Pulmonary Pharmacology & Therapeutics

Papers
(The H4-Index of Pulmonary Pharmacology & Therapeutics is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Celebrating the appointment of Mario Cazzola as Honorary Editor of Pulmonary Pharmacology & Therapeutics94
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies37
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study30
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)28
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d27
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients25
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation20
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens20
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function18
Editorial Board17
Editorial Board16
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential16
Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis14
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets14
0.098807096481323